公开(公告)号：US20220280643A1

公开(公告)日：2022-09-08

申请号：US17631847

申请日：2020-07-28

申请人： Mark WHITE ,  Compugen Ltd.

发明人： Mark WHITE ,  Adeboye Henry ADEWOYE ,  Michael BUCKLEY ,  Jun LU ,  John HUNTER ,  Anat COHEN DAYAG

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K47/22 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26 ,  A61P35/00

摘要： The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof.

公开(公告)号：US20240082397A1

公开(公告)日：2024-03-14

申请号：US18263171

申请日：2022-01-28

申请人： COMPUGEN LTD.

发明人： Mark WHITE ,  Inbal BARBIRO ,  Ilan VAKNIN ,  Assaf WOOL ,  Zurit LEVINE ,  Henry Adeboye ADEWOYE, MD ,  Michael BUCKLEY ,  Jun LU ,  John HUNTER ,  Anat COHEN-DAYAG ,  Gad S. COJOCARU ,  Eran OPHIR ,  Zoya ALTEBER

IPC分类号： A61K39/395 ,  A61K47/02 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K39/39591 ,  A61K47/02 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  C07K16/28 ,  A61K2039/505

摘要： The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.